Dr. Arul M. Chinnaiyan serves as Scientific Adviser at Tempus. He is an Investigator of the Howard Hughes Medical Institute, American Cancer Society Research Professor, and S.P. Hicks Endowed Professor of Pathology and Urology at the University of Michigan. He also serves as the inaugural Director of the Michigan Center for Translational Pathology (MCTP) which is comprised of a multi-disciplinary team of investigators focused on translating “-Omic” technologies to patient care in terms of biomarkers and novel therapeutics. He has co-authored over 400 manuscripts and has been designated an A. Alfred Taubman Medical Research Institute Scholar and is an elected member of the American Academy of Arts and Sciences (AAAS), the National Academy of Medicine (NAM), the Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI). He serves on the Board of Scientific Advisors for the National Cancer Institute. Dr. Chinnaiyan, who received his medical degree and doctorate in pathology from the U-M, has received a number of prestigious awards, including the Dean’s Basic Science Research Award, the Amgen Outstanding Investigator Award, and the Pew Biomedical Scholar Award. In 2008 he received the American Association of Cancer Research (AACR) Award for Outstanding Achievement in Cancer Research. In 2007 Dr. Chinnaiyan and his team were the recipients of the inaugural AACR Team Science Award. He has received a number of other prestigious awards including the 2009 Paul Marks Prize for Cancer Research, 2009 Philip Levine Award for Cancer Research, 2007 Ramzi Cotran Award from the United States and Canadian Academy of Pathology, 2005 Benjamin Castleman Award, and the 2005 Amgen Outstanding Investigator by the American Society of Investigative Pathology. Most recently, in 2013, he received the Distinguished University Innovator Award from the University of Michigan as well as the Urology Care Foundation’s Prostate Cancer Excellence Award.